lifestyle.pluralist.com

Author: Outlook Therapeutics, Inc.

Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

March 25, 2026
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

March 24, 2026
Outlook Therapeutics Announces Proposed Public Offering

March 23, 2026
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

March 16, 2026
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

March 5, 2026
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

February 19, 2026
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

February 17, 2026
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

February 12, 2026